SOLUTION

Biotech & Life Sciences Investments

At Jameel Health, we strive to accelerate access to modern medical care for those who need it most and also address unmet market need by providing integrated distribution and in-market services solutions for our partners, opening new opportunities across the developing world. But we’re also doing so much more to accelerate this access through our targeted investments.

Through its dedicated biotech fund, the JIMCO Life Sciences Fund, JIMCO is an active investor in innovative, early-stage, and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the economy of the global health sector, from pharmaceuticals and vaccines to cutting-edge medical devices, technologies, and techniques.

Featured Partner

Evelo Biosciences (NASDAQ: EVLO) is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. Cells in the small intestine are known to play a central role in governing the body’s immune, metabolic, and neurological systems.

Evelo Biosciences has created an integrated platform to develop a range of oral biologics which harness this central role, and the efficiency of their platform has allowed Evelo to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases, including the treatment of COVID-19 and many cancers.

Visit: Evelo Biosciences